In any due diligence process, knowing the assumptions that drive the value estimate and the methodology used to balance anticipated investments, risks, and rewards will allow for a company to adjust the diligence review accordingly. This discussion will cover:
- Approaches for developing valuation and valuation assumptions for in-licensing, M&A, IPO, and R&D
- Evaluating the future impact of key items when reviewing a biotech IP portfolio
- Identifying factors that executives use to arrive at a starting value, and then quantifying the deductions depending on the results of the IP due diligence
- Valuation methodologies used for early-stage vs. late-stage products
Panelists include: Gregg Alton, Senior Vice President and General Counsel, Gilead Sciences, Inc.; Doug Crawford, Associate Executive Director, QB3; Doug Sheehy, Vice President & General Counsel, Codexis, Inc.; and Paul Stewart, Partner, Foley.
Related Insights
May 29, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
May 29, 2025
Foley Viewpoints
Supreme Court Clarifies Scope of Federal Fraud Statutes in Connection with False DBE Reporting on Federally Funded Projects
On May 22, 2025, the U.S. Supreme Court issued a significant decision in Kousisis v. United States, affirming a six-year prison sentence for a contractor convicted of federal wire fraud for misrepresenting use of a disadvantaged business enterprise supplier on a project.
May 29, 2025
Foley Viewpoints
Keep Wining: Franchise Statute Opens Door to Protections for Missouri Wine Distributor
The Eighth Circuit recently applied a novel, broad reading of the Missouri Franchise Act granting franchise protection to distributors…